台湾地区幽门螺杆菌感染一线治疗:混合疗法、高剂量双联疗法与铋剂四联疗法的多中心开放标签随机试验
该多中心开放标签随机试验纳入台湾9中心918例成人幽门螺杆菌感染者,随机接受14天混合疗法、14天高剂量双联疗法或10天铋剂四联疗法。意向治疗分析根除率分别为91.5%、83.3%和90.2%,混合疗法和铋剂四联疗法均优于高剂量双联疗法且彼此相似;高剂量双联疗法不良事件最少。
要点
- 14天混合疗法根除率91.5%,优于14天高剂量双联疗法的83.3%。
- 10天铋剂四联疗法根除率90.2%,优于高剂量双联疗法。
- 高剂量双联疗法不良事件发生率13%,显著低于其他两组。
核心结论
- 14天混合疗法和10天铋剂四联疗法在台湾地区幽门螺杆菌一线治疗中疗效优于14天高剂量双联疗法。
- 高剂量双联疗法的不良反应少于混合疗法和铋剂四联疗法。
研究设计与样本
- 多中心、开放标签、随机试验,从台湾9个中心招募成年幽门螺杆菌感染患者。
- 918例患者按1:1:1随机分配至14天混合疗法、14天高剂量双联疗法或10天铋剂四联疗法。
- 根除状态通过13C-尿素呼气试验确定,主要结局为意向治疗人群的根除率。
主要发现
- 意向治疗根除率:14天混合疗法91.5%(280/306;95%CI 88.4%-94.6%),14天高剂量双联疗法83.3%(255/306;95%CI 87.8%-95.0%),10天铋剂四联疗法90.2%(276/306;95%CI 87.8%-95.0%)。
- 混合疗法与高剂量双联疗法差异8.2%(95%CI 4.5%-11.9%;P=0.002),铋剂四联疗法与高剂量双联疗法差异6.9%(95%CI 1.6%-12.2%;P=0.012),混合疗法与铋剂四联疗法相似。
- 不良事件频率:14天混合疗法27%(81/303),14天高剂量双联疗法13%(40/305),10天铋剂四联疗法32%(96/303);高剂量双联疗法不良事件最少(均P<0.001)。
关键数值与推荐
- 14天混合疗法根除率91.5%(280/306;95%CI 88.4%-94.6%)。
- 14天高剂量双联疗法根除率83.3%(255/306;95%CI 87.8%-95.0%)。
- 10天铋剂四联疗法根除率90.2%(276/306;95%CI 87.8%-95.0%)。
- 混合疗法较高剂量双联疗法差异8.2%(95%CI 4.5%-11.9%;P=0.002)。
- 铋剂四联疗法较高剂量双联疗法差异6.9%(95%CI 1.6%-12.2%;P=0.012)。
临床怎么用
- 在台湾地区幽门螺杆菌一线治疗中,14天混合疗法和10天铋剂四联疗法较高剂量双联疗法更有效,但高剂量双联疗法不良反应更少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The study aimed to compare the efficacies and safety of 14-day hybrid therapy, 14-day high-dose dual therapy, and 10-day bismuth quadruple therapy in the first-line treatment of Helicobacter pylori infections. METHODS: In this multicenter, open-label, randomized trial, we recruited adult H. pylori -infected patients from 9 centers in Taiwan. Subjects were randomly assigned (1:1:1) to 14-day hybrid therapy, 14-day high-dose dual therapy, or 10-day bismuth quadruple therapy. Eradication status was determined by the 13 C-urea breath test. The primary outcome was the eradication rate of H. pylori assessed in the intention-to-treat population. RESULTS: Between August 1, 2018, and December 2021, 918 patients were randomly assigned in this study. The intention-to-treat eradication rates were 91.5% (280/306; 95% confidence interval [CI] 88.4%-94.6%) for 14-day hybrid therapy, 83.3% (255/306; 95% CI 87.8%-95.0%) for 14-day high-dose dual therapy, and 90.2% (276/306; 95% CI 87.8%-95.0%) for 10-day bismuth quadruple therapy. Both hybrid therapy (difference 8.2%; 95% CI 4.5%-11.9%; P = 0.002) and bismuth quadruple therapy (difference 6.9%; 95% CI 1.6%-12.2%; P = 0.012) were superior to high-dose dual therapy and were similar to one another. The frequency of adverse events was 27% (81/303) with 14-day hybrid therapy, 13% (40/305) with 14-day high-dose dual therapy, and 32% (96/303) with 10-day bismuth quadruple therapy. Patients receiving high-dose dual therapy had the fewest adverse events (both P < 0.001). DISCUSSION: Fourteen-day hybrid therapy and 10-day bismuth quadruple therapy are more effective than 14-day high-dose dual therapy in the first-line treatment of H. pylori infection in Taiwan. However, high-dose dual therapy has fewer adverse effects than hybrid bismuth quadruple therapies.
引用
- Hsu PI, Chen KY, Tai WC, et al. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023. PMID: 36940437. doi:10.14309/ajg.0000000000002255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。